A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

660 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

NCT05173493

Helicobacter Pylori Infection

COMPLETED

The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

NCT04810793

Helicobacter Pylori

COMPLETED

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

NCT05620602

Helicobacter Pylori Infection

UNKNOWN

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

NCT05620589

Helicobacter Pylori Infection

UNKNOWN

Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)

NCT05997433

Helicobacter Pylori Infection

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment inpatients with Hp eradication failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group A

Within 3 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.

Remedial treatment within 3 months

Intervention Type OTHER

Remedial therapy was performed within 3 months

group B

Within 3 to 6 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.

Remedial treatment within 3 to 6 months

Intervention Type OTHER

Remedial therapy was performed within 3 to 6 months

group C

Within 6 to 12 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.

Remedial treatment within 6 to 12 months

Intervention Type OTHER

Remedial therapy was performed within 6 to 12 months

group D

After 12 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.

Remedial treatment after 12 months

Intervention Type OTHER

Remedial therapy was performed after 12 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remedial treatment within 3 months

Remedial therapy was performed within 3 months

Intervention Type OTHER

Remedial treatment within 3 to 6 months

Remedial therapy was performed within 3 to 6 months

Intervention Type OTHER

Remedial treatment within 6 to 12 months

Remedial therapy was performed within 6 to 12 months

Intervention Type OTHER

Remedial treatment after 12 months

Remedial therapy was performed after 12 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18-70 with H. pylori infection.
* Patients with previous Helicobacter pylori eradication.

Exclusion Criteria

* Patients treated with H2-receptor antagonist, PPI, bismuth and antibioticsin the previous 4 weeks.
* Patients with gastrectomy, acute GI bleeding and advanced gastric cancer.
* Patients with known or suspected allergy to study medications.
* Currently pregnant or lactating.
* Inability to provide informed consent and other situations that couldinterfere with the examination or therapeutic protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No